In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin
[Display omitted] Simvastatin (SV) is marketed as a lactone ester prodrug which is hydrolyzed to the active simvastatin hydroxyacid (SVA). SV is characterized by a low solubility and undergoes extensive first-pass metabolism. In this study, the influence of the upper gastrointestinal environment on...
Gespeichert in:
Veröffentlicht in: | International journal of pharmaceutics 2016-08, Vol.510 (1), p.296-303 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 303 |
---|---|
container_issue | 1 |
container_start_page | 296 |
container_title | International journal of pharmaceutics |
container_volume | 510 |
creator | Geboers, Sophie Stappaerts, Jef Tack, Jan Annaert, Pieter Augustijns, Patrick |
description | [Display omitted]
Simvastatin (SV) is marketed as a lactone ester prodrug which is hydrolyzed to the active simvastatin hydroxyacid (SVA). SV is characterized by a low solubility and undergoes extensive first-pass metabolism. In this study, the influence of the upper gastrointestinal environment on the intraluminal behavior of simvastatin was investigated by a series of in vitro experiments. Dissolution, stability and two-stage dissolution tests were performed using simulated and human gastrointestinal fluids.
The dissolution studies revealed a relatively slow dissolution of SV as well as conversion of SV to SVA. The hydrolysis of SV was further examined and stability studies indicated a faster conversion in gastric fluids than in intestinal fluids. These isolated phenomena were then confirmed by the more integrative two-stage dissolution studies.
To estimate the predictive value of the in vitro tests, an additional in vivo study was performed in which the gastrointestinal concentration-time profiles also revealed a slow dissolution of SV and faster degradation of SV to SVA in the stomach than in the intestinal tract. However, the plasma concentrations of SV and SVA did not directly correlate with the observed gastrointestinal concentrations, suggesting that gut wall and hepatic metabolism have a greater impact on systemic exposure of SV than the intraluminal interconversion between SV and SVA. |
doi_str_mv | 10.1016/j.ijpharm.2016.06.048 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1807895564</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517316305245</els_id><sourcerecordid>1807895564</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-626599998cb704ef97866970b0f09a0d0268bdfc96f2a6890b3ba69d30f564a03</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMo7rr6E5QevXSdNG0-TiLix8KCIHoOaZvsprTNmnQL_ntTdvXqMDAM87yZzIvQNYYlBkzvmqVtdlvlu2UW2yXEzPkJmmPOSEpyRk_RHAjjaYEZmaGLEBoAoBkm52iWMZIDZGKO3ld9MtrBu0T1dWKnZnSxjjoMdqMG6_rEmWTY6mSjQuRsP0yjXrVJqbdqtM5PQLDdGOdR0F-iM6PaoK-OdYE-n58-Hl_T9dvL6vFhnVaEFkNKM1qIGLwqGeTaCMYpFQxKMCAU1JBRXtamEtRkinIBJSkVFTUBU9BcAVmg28O7O---9vFTsrOh0m2reu32QWIOjIsiwhEtDmjlXQheG7nztlP-W2KQk52ykUc75WSnhJg5j7qb44p92en6T_XrXwTuD4COh45Wexkqq_tK19brapC1s_-s-AGLf4lR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1807895564</pqid></control><display><type>article</type><title>In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Geboers, Sophie ; Stappaerts, Jef ; Tack, Jan ; Annaert, Pieter ; Augustijns, Patrick</creator><creatorcontrib>Geboers, Sophie ; Stappaerts, Jef ; Tack, Jan ; Annaert, Pieter ; Augustijns, Patrick</creatorcontrib><description>[Display omitted]
Simvastatin (SV) is marketed as a lactone ester prodrug which is hydrolyzed to the active simvastatin hydroxyacid (SVA). SV is characterized by a low solubility and undergoes extensive first-pass metabolism. In this study, the influence of the upper gastrointestinal environment on the intraluminal behavior of simvastatin was investigated by a series of in vitro experiments. Dissolution, stability and two-stage dissolution tests were performed using simulated and human gastrointestinal fluids.
The dissolution studies revealed a relatively slow dissolution of SV as well as conversion of SV to SVA. The hydrolysis of SV was further examined and stability studies indicated a faster conversion in gastric fluids than in intestinal fluids. These isolated phenomena were then confirmed by the more integrative two-stage dissolution studies.
To estimate the predictive value of the in vitro tests, an additional in vivo study was performed in which the gastrointestinal concentration-time profiles also revealed a slow dissolution of SV and faster degradation of SV to SVA in the stomach than in the intestinal tract. However, the plasma concentrations of SV and SVA did not directly correlate with the observed gastrointestinal concentrations, suggesting that gut wall and hepatic metabolism have a greater impact on systemic exposure of SV than the intraluminal interconversion between SV and SVA.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2016.06.048</identifier><identifier>PMID: 27340029</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Animals ; Clinical trial ; Female ; Gastrointestinal behavior ; Gastrointestinal Tract - drug effects ; Gastrointestinal Tract - secretion ; Human gastrointestinal fluids ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Male ; Prodrug ; Simvastatin ; Simvastatin - metabolism ; Simvastatin - pharmacology ; Simvastatin acid ; Swine ; Young Adult</subject><ispartof>International journal of pharmaceutics, 2016-08, Vol.510 (1), p.296-303</ispartof><rights>2016</rights><rights>Copyright © 2016. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-626599998cb704ef97866970b0f09a0d0268bdfc96f2a6890b3ba69d30f564a03</citedby><cites>FETCH-LOGICAL-c365t-626599998cb704ef97866970b0f09a0d0268bdfc96f2a6890b3ba69d30f564a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0378517316305245$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27340029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geboers, Sophie</creatorcontrib><creatorcontrib>Stappaerts, Jef</creatorcontrib><creatorcontrib>Tack, Jan</creatorcontrib><creatorcontrib>Annaert, Pieter</creatorcontrib><creatorcontrib>Augustijns, Patrick</creatorcontrib><title>In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted]
Simvastatin (SV) is marketed as a lactone ester prodrug which is hydrolyzed to the active simvastatin hydroxyacid (SVA). SV is characterized by a low solubility and undergoes extensive first-pass metabolism. In this study, the influence of the upper gastrointestinal environment on the intraluminal behavior of simvastatin was investigated by a series of in vitro experiments. Dissolution, stability and two-stage dissolution tests were performed using simulated and human gastrointestinal fluids.
The dissolution studies revealed a relatively slow dissolution of SV as well as conversion of SV to SVA. The hydrolysis of SV was further examined and stability studies indicated a faster conversion in gastric fluids than in intestinal fluids. These isolated phenomena were then confirmed by the more integrative two-stage dissolution studies.
To estimate the predictive value of the in vitro tests, an additional in vivo study was performed in which the gastrointestinal concentration-time profiles also revealed a slow dissolution of SV and faster degradation of SV to SVA in the stomach than in the intestinal tract. However, the plasma concentrations of SV and SVA did not directly correlate with the observed gastrointestinal concentrations, suggesting that gut wall and hepatic metabolism have a greater impact on systemic exposure of SV than the intraluminal interconversion between SV and SVA.</description><subject>Adult</subject><subject>Animals</subject><subject>Clinical trial</subject><subject>Female</subject><subject>Gastrointestinal behavior</subject><subject>Gastrointestinal Tract - drug effects</subject><subject>Gastrointestinal Tract - secretion</subject><subject>Human gastrointestinal fluids</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Male</subject><subject>Prodrug</subject><subject>Simvastatin</subject><subject>Simvastatin - metabolism</subject><subject>Simvastatin - pharmacology</subject><subject>Simvastatin acid</subject><subject>Swine</subject><subject>Young Adult</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMo7rr6E5QevXSdNG0-TiLix8KCIHoOaZvsprTNmnQL_ntTdvXqMDAM87yZzIvQNYYlBkzvmqVtdlvlu2UW2yXEzPkJmmPOSEpyRk_RHAjjaYEZmaGLEBoAoBkm52iWMZIDZGKO3ld9MtrBu0T1dWKnZnSxjjoMdqMG6_rEmWTY6mSjQuRsP0yjXrVJqbdqtM5PQLDdGOdR0F-iM6PaoK-OdYE-n58-Hl_T9dvL6vFhnVaEFkNKM1qIGLwqGeTaCMYpFQxKMCAU1JBRXtamEtRkinIBJSkVFTUBU9BcAVmg28O7O---9vFTsrOh0m2reu32QWIOjIsiwhEtDmjlXQheG7nztlP-W2KQk52ykUc75WSnhJg5j7qb44p92en6T_XrXwTuD4COh45Wexkqq_tK19brapC1s_-s-AGLf4lR</recordid><startdate>20160820</startdate><enddate>20160820</enddate><creator>Geboers, Sophie</creator><creator>Stappaerts, Jef</creator><creator>Tack, Jan</creator><creator>Annaert, Pieter</creator><creator>Augustijns, Patrick</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160820</creationdate><title>In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin</title><author>Geboers, Sophie ; Stappaerts, Jef ; Tack, Jan ; Annaert, Pieter ; Augustijns, Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-626599998cb704ef97866970b0f09a0d0268bdfc96f2a6890b3ba69d30f564a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Animals</topic><topic>Clinical trial</topic><topic>Female</topic><topic>Gastrointestinal behavior</topic><topic>Gastrointestinal Tract - drug effects</topic><topic>Gastrointestinal Tract - secretion</topic><topic>Human gastrointestinal fluids</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Male</topic><topic>Prodrug</topic><topic>Simvastatin</topic><topic>Simvastatin - metabolism</topic><topic>Simvastatin - pharmacology</topic><topic>Simvastatin acid</topic><topic>Swine</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geboers, Sophie</creatorcontrib><creatorcontrib>Stappaerts, Jef</creatorcontrib><creatorcontrib>Tack, Jan</creatorcontrib><creatorcontrib>Annaert, Pieter</creatorcontrib><creatorcontrib>Augustijns, Patrick</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geboers, Sophie</au><au>Stappaerts, Jef</au><au>Tack, Jan</au><au>Annaert, Pieter</au><au>Augustijns, Patrick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2016-08-20</date><risdate>2016</risdate><volume>510</volume><issue>1</issue><spage>296</spage><epage>303</epage><pages>296-303</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted]
Simvastatin (SV) is marketed as a lactone ester prodrug which is hydrolyzed to the active simvastatin hydroxyacid (SVA). SV is characterized by a low solubility and undergoes extensive first-pass metabolism. In this study, the influence of the upper gastrointestinal environment on the intraluminal behavior of simvastatin was investigated by a series of in vitro experiments. Dissolution, stability and two-stage dissolution tests were performed using simulated and human gastrointestinal fluids.
The dissolution studies revealed a relatively slow dissolution of SV as well as conversion of SV to SVA. The hydrolysis of SV was further examined and stability studies indicated a faster conversion in gastric fluids than in intestinal fluids. These isolated phenomena were then confirmed by the more integrative two-stage dissolution studies.
To estimate the predictive value of the in vitro tests, an additional in vivo study was performed in which the gastrointestinal concentration-time profiles also revealed a slow dissolution of SV and faster degradation of SV to SVA in the stomach than in the intestinal tract. However, the plasma concentrations of SV and SVA did not directly correlate with the observed gastrointestinal concentrations, suggesting that gut wall and hepatic metabolism have a greater impact on systemic exposure of SV than the intraluminal interconversion between SV and SVA.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27340029</pmid><doi>10.1016/j.ijpharm.2016.06.048</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-5173 |
ispartof | International journal of pharmaceutics, 2016-08, Vol.510 (1), p.296-303 |
issn | 0378-5173 1873-3476 |
language | eng |
recordid | cdi_proquest_miscellaneous_1807895564 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adult Animals Clinical trial Female Gastrointestinal behavior Gastrointestinal Tract - drug effects Gastrointestinal Tract - secretion Human gastrointestinal fluids Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Male Prodrug Simvastatin Simvastatin - metabolism Simvastatin - pharmacology Simvastatin acid Swine Young Adult |
title | In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T17%3A58%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20and%20in%20vivo%20investigation%20of%20the%20gastrointestinal%20behavior%20of%20simvastatin&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Geboers,%20Sophie&rft.date=2016-08-20&rft.volume=510&rft.issue=1&rft.spage=296&rft.epage=303&rft.pages=296-303&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2016.06.048&rft_dat=%3Cproquest_cross%3E1807895564%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1807895564&rft_id=info:pmid/27340029&rft_els_id=S0378517316305245&rfr_iscdi=true |